Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02283788 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization
A Phase 1 study of Epilepsy, sponsored by Bial - Portela C S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 1
- Study location
NCT02283788: Completed Phase 1 study of Epilepsy, sponsored by Bial - Portela C S.A..
NCT02283788 is a Phase 1 study of Epilepsy that has completed, run by Bial - Portela C S.A.. The registered enrollment target is 67 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02283788, a Phase 1 study of Epilepsy, has completed, sponsored by Bial - Portela C S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover trial to evaluate the effect of eslicarbazepine acetate on cardiac repolarization in healthy adult men and women
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG BIA 2-093
Study Locations (1)
Florida
- Comprehensive Phase OneTM - Miramar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
What the finished NCT02283788 record still lists
NCT02283788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02283788 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02283788 about?
NCT02283788 is a clinical study titled "Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization". A randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover trial to evaluate the effect of eslicarbazepine acetate on cardiac repolarization in healthy adult men and women
What is the current status of trial NCT02283788?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2007-03. Estimated completion is 2007-06.
What conditions does trial NCT02283788 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT02283788?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), BIA 2-093 (DRUG).
Who is sponsoring clinical trial NCT02283788?
This trial is sponsored by Bial - Portela C S.A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02283788 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02283788's enrollment target sits among peer trials
67 74th of 160 higher than 87 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Understanding Ketamine's Dissociative Effects (KD Study)
RECRUITING · Phase 1
-
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
RECRUITING · Phase 1
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
-
Microelectrode Recordings From the Vagus Nerve in Awake Humans
RECRUITING · Phase 1
-
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia